What does MNEI stand for?

Monocyte/Neutrophil Elastase Inhibitor

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Mon National Education Committee Mongolia Nature and Environment Consortium Model National Energy Code for Buildings (aka Model National Energy Code of Canada for Buildings 1997) Model National Energy Code for Houses (Canada) Mobile National Emergency Command Posts Materiel Need Engineering Development Mean Nuclear Elongation Factor Mutuelle Nationale des Étudiants de France (French national student insurance provider; name changed to LMDE in 2000) Maison de la Nature et de l'Environnement de l'Isère (French: House of Nature and the Environment of the Isère; environmental awareness association; Isère, France) Millennium National Events, Inc. (Nevada)		Minimum-Nephrotoxic-Effect Level Mnemonics Neatly Eliminate Man's Only Nemesis - Insufficient Cerebral Storage Massachusetts Networks Education Partnership, Inc. Multilateral Nuclear Environmental Programme for Russia (EU) Multilateral Nuclear Environmental Programme in the Russian Federation Ministry of National Education and Religious Affairs (Greece) Ministry of Education, Research and Technology (France) Matter of National Environmental Significance (Australia) MHI (Mitsubishi Heavy Industries) Nuclear Energy Systems, Inc. (Japan) Ministry of Non-Conventional Energy Sources (India)

Samples in periodicals archive:

For example, we are currently using IPT's expertise in a collaborative development of a proprietary recombinant monocyte/neutrophil elastase inhibitor for the treatment of cystic fibrosis.

IVAX Completes Acquisition of Privately-Held Developer of ...

IVAX has several respiratory new chemical entities (NCE's) in development, including a recombinant monocyte/neutrophil elastase inhibitor (rM/NEI) for the treatment of cystic fibrosis lung disease and a new compound with potential as a treatment for a broad range of inflammatory diseases of the lung.

IVAX Provides Update On Its Proprietary Products Pipeline

The collaboration is based on a proprietary recombinant monocyte/neutrophil elastase inhibitor (rM/NEI) discovered by CBR scientists with support from the National Institutes of Health and the Cystic Fibrosis Foundation, which will be delivered to the lungs of cystic fibrosis patients by means of an IVAX proprietary inhalation system.

IVAX to Develop Cystic Fibrosis Drug With Harvard Medical School ...